Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
- 1 July 2018
- journal article
- review article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 19 (4) , 301-314
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung CancerJournal of Clinical Oncology, 2013
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialThe Lancet Oncology, 2013
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyThe Lancet Oncology, 2013
- ALK in Lung Cancer: Past, Present, and FutureJournal of Clinical Oncology, 2013
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant DiseaseJournal of Clinical Oncology, 2013
- Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness AnalysisJournal of Thoracic Oncology, 2011
- Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2001